Nengchun Huang, MD
Neurology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 28
- 8 carriers
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: 059765 · 557754 · 757050 · Dominican Hospital · El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
28 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Huang’s office at (408) 376-0316 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
28 of 28 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A82711 · Current
Licensed to practise in California · since 2003 · expires 2028-09-30 · Shanghai Medical University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative sepsis rateComplications and deaths | 11.66 (8.02 to 15.3) · 412 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.168 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.169 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.489 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.01 (0.06 to 1.95) · 1,248 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.85 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 134.37 (94.33 to 174.41) · 132 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 54 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12 · 228 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 491 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 278 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,973 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.34) · 7,510 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,695 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.42 (1.44 to 5.4) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.26 (0 to 2.76) · 436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.85 (0.4 to 3.29) · 1,474 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.73 (3 to 14.46) · 437 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.58 (0.13 to 3.03) · 343 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.17) · 6,336 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.615 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.937 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 212 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 505 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 45 · 237 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.5 · 594 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.9 · 510 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.9 · 473 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.4 to 7.8) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13 (9.4 to 17.7) · 126 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 12.7 · 43 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.1 (9.4 to 15.4) · 1,585 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 390 cases | No different | Jan 2024 – Dec 2024 |
What patients said (774 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 77% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 48% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$543,769
Medicare paid this office $543,769 for 553 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 361 | $153,009 | $161 |
| Return visit (30+ min) | 372 | $84,887 | $116 |
| Botox | 31 | $42,465 | None |
| Advance care planning, first 30 minutes | 410 | $29,743 | $71 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 93 | $28,110 | $39 |
See all 27 services
| Long return visit (40+ min) | 361 | $153,009 | $161 |
| Return visit (30+ min) | 372 | $84,887 | $116 |
| Botox | 31 | $42,465 | None |
| Advance care planning, first 30 minutes | 410 | $29,743 | $71 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 93 | $28,110 | $39 |
| Exam of neurobehavioral status, first hour | 285 | $24,409 | $85 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 95 | $22,633 | $44 |
| New patient visit (60+ min) | 115 | $21,798 | $190 |
| Injection, incobotulinumtoxin a, 1 unit | 34 | $20,530 | None |
| Injection, rimabotulinumtoxinb, 100 units | 29 | $19,418 | None |
| Injection, abobotulinumtoxina, 5 units | 12 | $17,000 | None |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 55 | $14,744 | $122 |
| Ultrasonic guidance for needle placement | 81 | $10,265 | $58 |
| Face injection for nerve paralysis | 15 | $7,298 | $197 |
| Annual depression screening, 5 to 15 minutes | 237 | $5,780 | $24 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 20 | $5,542 | $142 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 207 | $5,026 | $13 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 14 | $4,440 | $178 |
| Short return visit (20+ min) | 39 | $4,028 | $88 |
| Transitional care management services for problem of high complexity | 12 | $3,298 | $275 |
| Telephone medical discussion with physician, 11-20 minutes | 33 | $3,263 | $88 |
| Telephone medical discussion with physician, 5-10 minutes | 44 | $3,195 | $56 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 74 | $2,949 | $29 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 46 | $2,821 | $52 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $1,501 | $115 |
| New patient visit (45+ min) | 11 | $1,233 | $112 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 15 | $724 | $40 |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
553 Original Medicare patients in 2024. Average age 77 · Under 65 3% · 85 and older 15% · Women 41% · Also on Medicaid 14% · Health risk score 1.50. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 66% · Dementia 39% · Depression 31% · Diabetes 22% · Coronary heart disease 22% · Atrial fibrillation 17% · Cancer 15% · Chronic kidney disease 14% · Heart failure 11% · Stroke 10% · COPD 8%.
The office billed $1,502,670, Medicare allowed $710,114 and paid $543,769; for 23,263 services of 38 kinds; $99,414 of it was for drugs given in the office and $444,355 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 553 | 23,263 | 77 | 1.50 | $1,502,670 | $543,769 |
| 2023 | 552 | 16,483 | 76 | 1.61 | $1,183,240 | $419,495 |
| 2022 | 553 | 19,285 | 77 | 1.55 | $1,235,800 | $478,943 |
| 2021 | 483 | 13,303 | 76 | 1.51 | $1,088,625 | $433,766 |
| 2020 | 482 | 11,147 | 76 | 1.62 | $808,775 | $307,280 |
| 2019 | 499 | 15,682 | 76 | 1.56 | $789,330 | $393,612 |
| 2018 | 477 | 15,435 | 76 | 1.56 | $784,340 | $457,514 |
| 2017 | 419 | 16,363 | 75 | 1.49 | $737,593 | $425,653 |
| 2016 | 403 | 13,120 | 76 | 1.59 | $679,600 | $397,244 |
| 2015 | 425 | 11,130 | 75 | 1.60 | $611,230 | $371,962 |
| 2014 | 394 | 12,384 | 76 | 1.46 | $572,670 | $338,255 |
| 2013 | 346 | 12,888 | 76 | 1.51 | $525,570 | $327,794 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 24 services
| Long return visit (40+ min) | 328 | $115,196 | $161 |
| Return visit (30+ min) | 307 | $55,775 | $104 |
| Botox | 19 | $28,957 | None |
| Advance care planning, first 30 minutes | 355 | $26,042 | $73 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 94 | $24,448 | $39 |
| New patient visit (60+ min) | 123 | $24,118 | $196 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 99 | $21,566 | $44 |
| Exam of neurobehavioral status, first hour | 207 | $17,743 | $86 |
| Injection, rimabotulinumtoxinb, 100 units | 24 | $14,162 | None |
| Injection, incobotulinumtoxin a, 1 unit | 19 | $11,188 | None |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 48 | $11,093 | $121 |
| Ultrasonic guidance for needle placement | 66 | $7,895 | $58 |
| Annual depression screening, 5 to 15 minutes | 244 | $5,742 | $24 |
| Telephone medical discussion with physician, 11-20 minutes | 49 | $5,543 | $83 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 12 | $4,719 | $163 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 183 | $3,925 | $12 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 12 | $3,569 | $143 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 55 | $3,340 | $50 |
| Short return visit (20+ min) | 27 | $2,884 | $85 |
| Telephone medical discussion with physician, 21-30 minutes | 26 | $2,872 | $106 |
| New patient visit (45+ min) | 17 | $2,629 | $155 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 61 | $2,572 | $30 |
| Telephone medical discussion with physician, 5-10 minutes | 30 | $1,720 | $49 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 16 | $911 | $36 |
2022: 26 services
| Long return visit (40+ min) | 298 | $103,267 | $160 |
| Return visit (30+ min) | 359 | $73,568 | $109 |
| Botox | 31 | $36,228 | None |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 101 | $31,115 | $40 |
| Advance care planning, first 30 minutes | 368 | $28,733 | $75 |
| Injection, abobotulinumtoxina, 5 units | 18 | $25,804 | None |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 106 | $22,540 | $45 |
| New patient visit (60+ min) | 103 | $20,632 | $200 |
| Injection, rimabotulinumtoxinb, 100 units | 28 | $20,334 | None |
| Exam of neurobehavioral status, first hour | 208 | $18,091 | $87 |
| Telephone medical discussion with physician, 5-10 minutes | 146 | $13,326 | $53 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 45 | $10,950 | $116 |
| Telephone medical discussion with physician, 11-20 minutes | 79 | $9,282 | $86 |
| Ultrasonic guidance for needle placement | 73 | $9,236 | $58 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 28 | $8,734 | $171 |
| Face injection for nerve paralysis | 16 | $6,162 | $199 |
| Annual depression screening, 5 to 15 minutes | 240 | $5,619 | $23 |
| Short return visit (20+ min) | 38 | $4,600 | $81 |
| New patient visit (45+ min) | 33 | $4,588 | $139 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 68 | $3,933 | $52 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 53 | $3,383 | $30 |
| Telephone medical discussion with physician, 21-30 minutes | 21 | $2,706 | $118 |
| Injection of chemical for paralysis of nerve muscles on arm or leg, 1-4 muscles, first extremity | 12 | $2,584 | $129 |
| Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | 22 | $2,268 | $95 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 93 | $1,557 | $13 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 15 | $923 | $40 |
2021: 25 services
| Long return visit (40+ min) | 284 | $114,577 | $154 |
| Return visit (30+ min) | 312 | $66,866 | $108 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 98 | $41,764 | $41 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 102 | $25,031 | $46 |
| Advance care planning, first 30 minutes | 310 | $24,805 | $78 |
| Injection, rimabotulinumtoxinb, 100 units | 26 | $18,160 | None |
| Exam of neurobehavioral status, first hour | 182 | $16,342 | $90 |
| Botox | 14 | $15,054 | None |
| New patient visit (60+ min) | 76 | $14,370 | $189 |
| Injection, abobotulinumtoxina, 5 units | 11 | $12,197 | None |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 44 | $10,893 | $115 |
| Telephone medical discussion with physician, 5-10 minutes | 105 | $8,795 | $54 |
| Ultrasonic guidance for needle placement | 55 | $7,022 | $58 |
| Telephone medical discussion with physician, 11-20 minutes | 62 | $6,843 | $86 |
| Injection, incobotulinumtoxin a, 1 unit | 15 | $6,468 | None |
| Short return visit (20+ min) | 44 | $6,102 | $81 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 18 | $5,567 | $164 |
| Annual depression screening, 5 to 15 minutes | 217 | $5,095 | $23 |
| New patient visit (45+ min) | 25 | $3,974 | $159 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 154 | $3,640 | $13 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $2,854 | $110 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 41 | $2,512 | $52 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 35 | $2,136 | $31 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 17 | $866 | $39 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 14 | $192 | $13 |
2020: 23 services
| Return visit (30+ min) | 358 | $61,070 | $80 |
| Long return visit (40+ min) | 234 | $56,900 | $116 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 97 | $25,083 | $41 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 108 | $19,137 | $46 |
| Advance care planning, first 30 minutes | 240 | $18,477 | $76 |
| New patient visit (60+ min) | 86 | $15,175 | $176 |
| Botox | 13 | $14,680 | None |
| Injection, abobotulinumtoxina, 5 units | 12 | $13,175 | None |
| Exam of neurobehavioral status, first hour | 115 | $10,528 | $91 |
| Injection, rimabotulinumtoxinb, 100 units | 18 | $9,388 | None |
| Short return visit (20+ min) | 118 | $8,367 | $53 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 34 | $7,474 | $112 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 15 | $6,197 | $167 |
| Ultrasonic guidance for needle placement | 47 | $5,865 | $57 |
| Injection, incobotulinumtoxin a, 1 unit | 13 | $5,189 | None |
| Face injection for nerve paralysis | 12 | $4,740 | $190 |
| Annual depression screening, 5 to 15 minutes | 203 | $4,598 | $23 |
| Extended office or other outpatient service, first hour | 34 | $4,446 | $120 |
| Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | 145 | $4,061 | $13 |
| New patient visit (45+ min) | 26 | $3,392 | $130 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 28 | $1,844 | $53 |
| Telephone medical discussion with physician, 5-10 minutes | 29 | $1,486 | $40 |
| Telephone medical discussion with physician, 11-20 minutes | 14 | $897 | $64 |
2019: 21 services
| Long return visit (40+ min) | 309 | $103,313 | $125 |
| Return visit (30+ min) | 267 | $48,732 | $94 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | 109 | $33,932 | $40 |
| Advance care planning, first 30 minutes | 324 | $24,306 | $74 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 115 | $24,265 | $45 |
| Exam of neurobehavioral status, first hour | 258 | $22,111 | $85 |
| Botox | 22 | $19,453 | None |
| Injection, incobotulinumtoxin a, 1 unit | 36 | $15,305 | None |
| New patient visit (60+ min) | 87 | $15,216 | $175 |
| Injection, rimabotulinumtoxinb, 100 units | 20 | $14,808 | None |
| Injection, abobotulinumtoxina, 5 units | 13 | $13,772 | None |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 56 | $9,994 | $100 |
| Extended office or other outpatient service, first hour | 60 | $9,216 | $117 |
| Ultrasonic guidance for needle placement | 72 | $7,554 | $55 |
| Face injection for nerve paralysis | 18 | $6,254 | $174 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 21 | $6,014 | $154 |
| Short return visit (20+ min) | 54 | $4,932 | $65 |
| New patient visit (45+ min) | 26 | $3,702 | $142 |
| Transitional care management services for problem of high complexity | 15 | $3,403 | $213 |
| Annual depression screening, 5 to 15 minutes | 140 | $3,052 | $22 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 18 | $1,126 | $51 |
2018: 21 services
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 116 | $140,135 | $228 |
| Return visit (30+ min) | 324 | $69,605 | $91 |
| Long return visit (40+ min) | 228 | $65,298 | $123 |
| Botox | 21 | $21,192 | None |
| Exam of neurobehavioral status, first hour | 194 | $16,250 | $83 |
| Injection, rimabotulinumtoxinb, 100 units | 28 | $16,220 | None |
| Injection, abobotulinumtoxina, 5 units | 16 | $15,228 | None |
| Advance care planning, first 30 minutes | 209 | $14,932 | $70 |
| Injection, incobotulinumtoxin a, 1 unit | 24 | $14,257 | None |
| Short return visit (20+ min) | 153 | $13,892 | $61 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 47 | $10,567 | $99 |
| New patient visit (45+ min) | 67 | $9,641 | $144 |
| New patient visit (60+ min) | 53 | $9,448 | $178 |
| Ultrasonic guidance for needle placement | 70 | $8,541 | $58 |
| Face injection for nerve paralysis | 18 | $6,721 | $168 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 22 | $5,507 | $153 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system | 16 | $3,841 | $98 |
| Transitional care management services for problem of high complexity | 13 | $3,112 | $222 |
| Annual depression screening, 5 to 15 minutes | 141 | $3,100 | $22 |
| Extended office or other outpatient service, first hour | 19 | $2,808 | $117 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 33 | $1,961 | $52 |
2017: 22 services
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 108 | $129,474 | $222 |
| Return visit (30+ min) | 288 | $67,046 | $91 |
| Long return visit (40+ min) | 172 | $45,940 | $121 |
| Injection, abobotulinumtoxina, 5 units | 18 | $26,519 | None |
| Botox | 34 | $25,263 | None |
| Short return visit (20+ min) | 165 | $18,253 | $60 |
| Injection, rimabotulinumtoxinb, 100 units | 29 | $15,558 | None |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 55 | $11,113 | $93 |
| Ultrasonic guidance for needle placement | 81 | $10,341 | $59 |
| Exam of neurobehavioral status, first hour | 129 | $10,235 | $79 |
| New patient visit (60+ min) | 56 | $9,859 | $176 |
| Face injection for nerve paralysis | 21 | $7,947 | $177 |
| Injection, incobotulinumtoxin a, 1 unit | 16 | $7,387 | None |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 29 | $7,266 | $132 |
| New patient visit (45+ min) | 40 | $5,387 | $135 |
| Advance care planning, first 30 minutes | 80 | $5,229 | $65 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system | 19 | $4,862 | $90 |
| Annual depression screening, 5 to 15 minutes | 152 | $3,357 | $22 |
| Extended office or other outpatient service, first hour | 26 | $3,130 | $116 |
| Transitional care management services for problem of high complexity | 13 | $2,937 | $210 |
| Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | 12 | $1,597 | $100 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 25 | $1,595 | $51 |
2016: 20 services
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 99 | $116,657 | $220 |
| Return visit (30+ min) | 287 | $66,862 | $91 |
| Long return visit (40+ min) | 175 | $39,289 | $117 |
| Injection, abobotulinumtoxina, 5 units | 16 | $22,996 | None |
| Short return visit (20+ min) | 172 | $21,792 | $65 |
| Botox | 29 | $21,031 | None |
| Exam of neurobehavioral status, first hour | 201 | $18,048 | $80 |
| Injection, rimabotulinumtoxinb, 100 units | 31 | $15,085 | None |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 49 | $10,172 | $94 |
| Advance care planning, first 30 minutes | 123 | $9,498 | $77 |
| New patient visit (60+ min) | 51 | $8,925 | $175 |
| Ultrasonic guidance for needle placement | 66 | $8,770 | $59 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 23 | $6,409 | $139 |
| Face injection for nerve paralysis | 16 | $5,406 | $180 |
| New patient visit (45+ min) | 33 | $4,997 | $151 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system | 23 | $4,930 | $97 |
| Extended office or other outpatient service, first hour | 31 | $3,314 | $90 |
| Annual depression screening, 5 to 15 minutes | 72 | $1,572 | $22 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 22 | $1,528 | $51 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 12 | $1,161 | $68 |
2015: 17 services
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 96 | $113,481 | $228 |
| Return visit (30+ min) | 291 | $70,962 | $95 |
| Long return visit (40+ min) | 188 | $48,708 | $121 |
| Botox | 32 | $23,437 | None |
| Short return visit (20+ min) | 158 | $18,954 | $67 |
| New patient visit (60+ min) | 91 | $15,750 | $173 |
| Exam of neurobehavioral status, first hour | 157 | $15,069 | $82 |
| Injection, rimabotulinumtoxinb, 100 units | 31 | $14,603 | None |
| Injection, abobotulinumtoxina, 5 units | 12 | $9,432 | None |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 43 | $9,027 | $99 |
| Ultrasonic guidance for needle placement | 57 | $6,863 | $58 |
| New patient visit (45+ min) | 33 | $4,731 | $143 |
| Face injection for nerve paralysis | 15 | $4,383 | $183 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system | 18 | $4,116 | $100 |
| Extended office or other outpatient service, first hour | 36 | $3,881 | $90 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 18 | $3,747 | $125 |
| Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | 14 | $765 | $51 |
2014: 15 services
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 72 | $81,777 | $229 |
| Return visit (30+ min) | 262 | $67,017 | $93 |
| Long return visit (40+ min) | 190 | $51,615 | $122 |
| Botox | 30 | $25,914 | None |
| Exam of neurobehavioral status, first hour | 161 | $17,581 | $83 |
| Injection, rimabotulinumtoxinb, 100 units | 29 | $14,966 | None |
| New patient visit (60+ min) | 80 | $14,043 | $176 |
| Injection, abobotulinumtoxina, 5 units | 13 | $12,141 | None |
| Short return visit (20+ min) | 108 | $10,787 | $66 |
| Ultrasonic guidance for needle placement | 55 | $9,420 | $71 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 36 | $8,135 | $98 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 21 | $6,341 | $132 |
| New patient visit (45+ min) | 39 | $5,524 | $142 |
| Extended office or other outpatient service, first hour | 37 | $3,792 | $88 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system | 17 | $2,695 | $100 |
2013: 19 services
| Return visit (30+ min) | 258 | $70,956 | $91 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system, first hour | 65 | $68,828 | $227 |
| Long return visit (40+ min) | 147 | $33,572 | $121 |
| Botox | 31 | $26,671 | None |
| Ultrasonic guidance for needle placement | 59 | $26,497 | $210 |
| Injection, rimabotulinumtoxinb, 100 units | 31 | $15,389 | None |
| Injection, abobotulinumtoxina, 5 units | 18 | $13,257 | None |
| Short return visit (20+ min) | 117 | $11,119 | $64 |
| Extended office or other outpatient service, first hour | 90 | $10,236 | $86 |
| Exam of neurobehavioral status, first hour | 82 | $9,631 | $78 |
| New patient visit (60+ min) | 49 | $8,510 | $174 |
| Injection of chemical for paralysis of salivary glands on both sides of mouth | 33 | $7,132 | $96 |
| Face injection for nerve paralysis | 15 | $5,835 | $188 |
| Injection of chemical for destruction of neck muscles | 18 | $5,418 | $159 |
| Injection of chemical for destruction of arms legs and/or torso muscles | 14 | $3,815 | $159 |
| New patient visit (45+ min) | 23 | $3,467 | $151 |
| Electronic analysis and programming of implanted complex deep brain neurostimulator generator system | 16 | $3,063 | $99 |
| New patient visit (30+ min) | 13 | $1,323 | $102 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 14 | $1,256 | $70 |
Drugs they prescribed that Part D paid
$2,882,440
Pharmacies billed $2,882,440 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (12 of 6,889) in 2024. Above the middle of the specialty; the typical neurology clinician is at 0%.
4,923 generic and 1,966 brand-name prescriptions · $2,882,440 in drug cost · 409 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rytary | Parkinson's | 1,439 | $1,328,038 | $923 |
| Apokyn | None | 15 | $324,782 | $21,652 |
| Nuplazid | Parkinson's psychosis | 48 | $288,363 | $6,008 |
| Gocovri | None | 103 | $228,932 | $2,223 |
| Nourianz | None | 34 | $84,667 | $2,490 |
See all 57 drugs
| Rytary | Parkinson's | 1,439 | $1,328,038 | $923 |
| Apokyn | None | 15 | $324,782 | $21,652 |
| Nuplazid | Parkinson's psychosis | 48 | $288,363 | $6,008 |
| Gocovri | None | 103 | $228,932 | $2,223 |
| Nourianz | None | 34 | $84,667 | $2,490 |
| Carbidopa-Levodopa | None | 1,215 | $47,911 | $39 |
| Neupro | None | 39 | $41,300 | $1,059 |
| Ropinirole Er | None | 246 | $39,233 | $159 |
| Entacapone | None | 164 | $33,067 | $202 |
| Gemtesa | None | 48 | $28,641 | $597 |
| Xadago | None | 22 | $26,326 | $1,197 |
| Amantadine | None | 553 | $20,436 | $37 |
| Ongentys | None | 20 | $18,158 | $908 |
| Myrbetriq | None | 24 | $16,690 | $695 |
| Pramipexole Er | None | 30 | $14,531 | $484 |
| Carbidopa-Levodopa-Entacapone | None | 33 | $14,225 | $431 |
| Botox | None | 21 | $13,190 | $628 |
| Rivastigmine | None | 49 | $12,391 | $253 |
| Carbidopa-Levodopa Er | None | 165 | $12,123 | $73 |
| Rasagiline Mesylate | None | 79 | $10,611 | $134 |
| Myobloc | None | 18 | $7,186 | $399 |
| Pramipexole Dihydrochloride | None | 217 | $5,996 | $28 |
| Midodrine | None | 89 | $4,975 | $56 |
| Quetiapine | None | 206 | $3,987 | $19 |
| Donepezil | None | 290 | $3,648 | $13 |
| Selegiline | None | 45 | $3,138 | $70 |
| Escitalopram | None | 263 | $2,932 | $11 |
| Mirtazapine | None | 118 | $2,902 | $25 |
| Clozapine | None | 125 | $2,883 | $23 |
| Gabapentin | None | 148 | $1,979 | $13 |
| Fludrocortisone Acetate | None | 93 | $1,674 | $18 |
| Clozapine Odt | None | 37 | $1,389 | $38 |
| Duloxetine | None | 43 | $1,378 | $32 |
| Memantine | None | 30 | $1,100 | $37 |
| Propranolol Hcl Er | None | 31 | $1,056 | $34 |
| Clonazepam | None | 148 | $1,036 | $7 |
| Amoxapine | None | 11 | $931 | $85 |
| Tolterodine Tartrate Er | None | 14 | $840 | $60 |
| Atomoxetine | None | 21 | $838 | $40 |
| Bupropion Hcl Sr | None | 20 | $685 | $34 |
| Oxybutynin Chloride Er | None | 15 | $675 | $45 |
| Propranolol | None | 28 | $624 | $22 |
| Pregabalin | None | 23 | $573 | $25 |
| Trazodone | None | 57 | $564 | $10 |
| Galantamine Hbr | None | 14 | $540 | $39 |
| Glycopyrrolate | None | 17 | $372 | $22 |
| Lorazepam | None | 52 | $327 | $6 |
| Primidone | None | 39 | $290 | $7 |
| Buspirone | None | 13 | $272 | $21 |
| Levetiracetam | None | 12 | $270 | $23 |
| Ropinirole | None | 14 | $267 | $19 |
| Bupropion Xl | None | 21 | $218 | $10 |
| Alprazolam | None | 25 | $213 | $9 |
| Cyclobenzaprine | None | 16 | $192 | $12 |
| Citalopram Hbr | None | 11 | $172 | $16 |
| Sertraline | None | 24 | $77 | $3 |
| Tramadol | None | 12 | $41 | $3 |
Year by year
| 2024 | 6,889 | 579 | 0% (12) | 29% | $2,882,440 |
| 2023 | 6,584 | 541 | 0% (14) | 29% | $3,012,438 |
| 2022 | 6,413 | 518 | 0% (17) | None | $3,397,525 |
| 2021 | 6,089 | 463 | 0% (16) | None | $3,072,467 |
| 2020 | 5,921 | 440 | 0% (12) | None | $2,473,354 |
| 2019 | 6,405 | 417 | 0% (18) | 26% | $2,118,525 |
| 2018 | 6,179 | 390 | 0% (13) | 19% | $1,562,384 |
| 2017 | 6,128 | 332 | None | 16% | $1,109,138 |
| 2016 | 6,286 | 329 | 0% (16) | 20% | $1,231,888 |
| 2015 | 5,800 | 324 | 0% (16) | 17% | $894,666 |
| 2014 | 5,125 | 272 | None | None | $674,482 |
| 2013 | 4,865 | 261 | 0% (11) | 18% | $629,241 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 53 drugs
| Rytary | Parkinson's | 1,332 | $1,438,879 | $1,080 |
| Nuplazid | Parkinson's psychosis | 60 | $354,524 | $5,909 |
| Gocovri | None | 99 | $193,561 | $1,955 |
| Nourianz | None | 74 | $180,382 | $2,438 |
| Carbidopa-Levodopa | None | 1,029 | $61,950 | $60 |
| Ropinirole Er | None | 218 | $50,423 | $231 |
| Neupro | None | 34 | $40,168 | $1,181 |
| Ongentys | None | 40 | $38,783 | $970 |
| Entacapone | None | 135 | $27,802 | $206 |
| Pramipexole Er | None | 37 | $26,383 | $713 |
| Xadago | None | 20 | $23,901 | $1,195 |
| Rivastigmine | None | 96 | $22,624 | $236 |
| Myrbetriq | None | 31 | $22,018 | $710 |
| Amantadine | None | 553 | $21,880 | $40 |
| Rasagiline Mesylate | None | 99 | $16,957 | $171 |
| Carbidopa-Levodopa-Entacapone | None | 26 | $16,065 | $618 |
| Carbidopa-Levodopa Er | None | 141 | $14,362 | $102 |
| Nuedexta | None | 13 | $13,658 | $1,051 |
| Midodrine | None | 66 | $11,758 | $178 |
| Myobloc | None | 12 | $8,440 | $703 |
| Pramipexole Dihydrochloride | None | 234 | $8,246 | $35 |
| Donepezil | None | 330 | $5,796 | $18 |
| Selegiline | None | 63 | $5,671 | $90 |
| Quetiapine | None | 205 | $4,335 | $21 |
| Memantine Hcl Er | None | 16 | $4,264 | $266 |
| Escitalopram | None | 300 | $3,777 | $13 |
| Mirtazapine | None | 90 | $2,986 | $33 |
| Fludrocortisone Acetate | None | 78 | $2,664 | $34 |
| Propranolol Hcl Er | None | 39 | $2,289 | $59 |
| Clozapine Odt | None | 76 | $1,977 | $26 |
| Duloxetine | None | 47 | $1,614 | $34 |
| Tolterodine Tartrate Er | None | 20 | $1,448 | $72 |
| Ropinirole | None | 27 | $1,399 | $52 |
| Gabapentin | None | 93 | $1,271 | $14 |
| Clonazepam | None | 146 | $1,171 | $8 |
| Clozapine | None | 59 | $1,085 | $18 |
| Amoxapine | None | 12 | $1,056 | $88 |
| Memantine | None | 19 | $1,047 | $55 |
| Rivastigmine | None | 23 | $953 | $41 |
| Droxidopa | None | 12 | $944 | $79 |
| Bupropion Hcl Sr | None | 13 | $779 | $60 |
| Trazodone | None | 84 | $764 | $9 |
| Alprazolam | None | 21 | $534 | $25 |
| Sertraline | None | 42 | $486 | $12 |
| Paroxetine | None | 12 | $287 | $24 |
| Primidone | None | 25 | $284 | $11 |
| Lorazepam | None | 63 | $263 | $4 |
| Citalopram Hbr | None | 11 | $262 | $24 |
| Propranolol | None | 17 | $261 | $15 |
| Bupropion Xl | None | 22 | $190 | $9 |
| Cyclobenzaprine | None | 16 | $141 | $9 |
| Ondansetron | None | 13 | $51 | $4 |
| Tramadol | None | 12 | $38 | $3 |
2022: 57 drugs
| Rytary | Parkinson's | 1,350 | $1,327,193 | $983 |
| Apokyn | None | 22 | $486,060 | $22,094 |
| Nuplazid | Parkinson's psychosis | 54 | $320,888 | $5,942 |
| Northera | None | 11 | $232,861 | $21,169 |
| Gocovri | None | 102 | $194,331 | $1,905 |
| Nourianz | None | 91 | $191,604 | $2,106 |
| Carbidopa-Levodopa | None | 949 | $57,504 | $61 |
| Ongentys | None | 65 | $54,470 | $838 |
| Ropinirole Er | None | 214 | $52,032 | $243 |
| Neupro | None | 39 | $49,889 | $1,279 |
| Rivastigmine | None | 175 | $45,481 | $260 |
| Nuedexta | None | 27 | $35,101 | $1,300 |
| Rasagiline Mesylate | None | 75 | $33,948 | $453 |
| Entacapone | None | 156 | $33,319 | $214 |
| Myrbetriq | None | 38 | $26,625 | $701 |
| Pramipexole Er | None | 30 | $26,272 | $876 |
| Xadago | None | 16 | $24,170 | $1,511 |
| Amantadine | None | 425 | $22,363 | $53 |
| Botox | None | 17 | $19,994 | $1,176 |
| Carbidopa-Levodopa Er | None | 116 | $12,293 | $106 |
| Midodrine | None | 67 | $10,829 | $162 |
| Carbidopa-Levodopa-Entacapone | None | 18 | $9,220 | $512 |
| Myobloc | None | 14 | $8,789 | $628 |
| Osmolex Er | None | 14 | $8,453 | $604 |
| Sinemet 25-100 | None | 13 | $7,514 | $578 |
| Quetiapine | None | 226 | $6,193 | $27 |
| Pramipexole Dihydrochloride | None | 181 | $6,009 | $33 |
| Memantine Hcl Er | None | 20 | $5,858 | $293 |
| Donepezil | None | 318 | $5,658 | $18 |
| Selegiline | None | 61 | $5,049 | $83 |
| Fludrocortisone Acetate | None | 62 | $2,679 | $43 |
| Propranolol Hcl Er | None | 23 | $2,495 | $108 |
| Mirtazapine | None | 94 | $2,334 | $25 |
| Galantamine Hbr | None | 22 | $2,223 | $101 |
| Escitalopram | None | 147 | $2,067 | $14 |
| Pregabalin | None | 40 | $1,822 | $46 |
| Rivastigmine | None | 26 | $1,808 | $70 |
| Clozapine | None | 100 | $1,672 | $17 |
| Memantine | None | 29 | $1,576 | $54 |
| Gabapentin | None | 72 | $1,474 | $20 |
| Clonazepam | None | 207 | $1,452 | $7 |
| Ropinirole | None | 45 | $1,391 | $31 |
| Duloxetine | None | 71 | $1,308 | $18 |
| Amoxapine | None | 12 | $1,144 | $95 |
| Tolterodine Tartrate Er | None | 13 | $1,047 | $81 |
| Bupropion Hcl Sr | None | 15 | $703 | $47 |
| Lorazepam | None | 97 | $664 | $7 |
| Trazodone | None | 67 | $533 | $8 |
| Paroxetine | None | 18 | $511 | $28 |
| Clozapine Odt | None | 25 | $397 | $16 |
| Sertraline | None | 24 | $341 | $14 |
| Primidone | None | 27 | $332 | $12 |
| Alprazolam | None | 29 | $218 | $8 |
| Cyclobenzaprine | None | 15 | $211 | $14 |
| Tamsulosin | None | 16 | $80 | $5 |
| Ondansetron | None | 15 | $38 | $3 |
| Tramadol | None | 12 | $28 | $2 |
2021: 56 drugs
| Rytary | Parkinson's | 1,331 | $1,214,226 | $912 |
| Nuplazid | Parkinson's psychosis | 90 | $538,635 | $5,985 |
| Northera | None | 14 | $271,857 | $19,418 |
| Gocovri | None | 105 | $174,961 | $1,666 |
| Nourianz | None | 54 | $91,019 | $1,686 |
| Rivastigmine | None | 207 | $60,886 | $294 |
| Ropinirole Er | None | 280 | $58,333 | $208 |
| Carbidopa-Levodopa | None | 774 | $53,044 | $69 |
| Ongentys | None | 63 | $47,370 | $752 |
| Rasagiline Mesylate | None | 99 | $47,239 | $477 |
| Neupro | None | 38 | $44,897 | $1,181 |
| Kynmobi | None | 18 | $42,249 | $2,347 |
| Myrbetriq | None | 52 | $38,262 | $736 |
| Nuedexta | None | 20 | $27,694 | $1,385 |
| Xadago | None | 17 | $22,842 | $1,344 |
| Entacapone | None | 153 | $22,513 | $147 |
| Amantadine | None | 388 | $21,063 | $54 |
| Carbidopa-Levodopa-Entacapone | None | 29 | $15,128 | $522 |
| Pramipexole Er | None | 27 | $14,186 | $525 |
| Carbidopa-Levodopa Er | None | 99 | $12,806 | $129 |
| Osmolex Er | None | 16 | $11,539 | $721 |
| Myobloc | None | 14 | $8,255 | $590 |
| Midodrine | None | 43 | $6,930 | $161 |
| Pramipexole Dihydrochloride | None | 192 | $6,422 | $33 |
| Linzess | None | 13 | $5,950 | $458 |
| Quetiapine | None | 201 | $4,563 | $23 |
| Selegiline | None | 42 | $4,443 | $106 |
| Donepezil | None | 245 | $4,192 | $17 |
| Galantamine Hbr | None | 41 | $3,584 | $87 |
| Pregabalin | None | 31 | $3,030 | $98 |
| Mirtazapine | None | 106 | $2,761 | $26 |
| Propranolol Hcl Er | None | 25 | $2,245 | $90 |
| Clozapine | None | 109 | $2,132 | $20 |
| Memantine Hcl Er | None | 11 | $2,092 | $190 |
| Fludrocortisone Acetate | None | 63 | $1,886 | $30 |
| Memantine | None | 26 | $1,844 | $71 |
| Ropinirole | None | 52 | $1,739 | $33 |
| Clonazepam | None | 208 | $1,686 | $8 |
| Escitalopram | None | 133 | $1,681 | $13 |
| Ipratropium | None | 19 | $1,455 | $77 |
| Rivastigmine | None | 17 | $1,293 | $76 |
| Amoxapine | None | 12 | $989 | $82 |
| Baclofen | None | 13 | $944 | $73 |
| Gabapentin | None | 70 | $918 | $13 |
| Trazodone | None | 63 | $611 | $10 |
| Duloxetine | None | 31 | $559 | $18 |
| Zonisamide | None | 11 | $540 | $49 |
| Solifenacin | None | 12 | $497 | $41 |
| Paroxetine | None | 15 | $461 | $31 |
| Sertraline | None | 23 | $456 | $20 |
| Lorazepam | None | 75 | $414 | $6 |
| Propranolol | None | 16 | $379 | $24 |
| Alprazolam | None | 43 | $331 | $8 |
| Tramadol | None | 12 | $196 | $16 |
| Fluoxetine | None | 13 | $154 | $12 |
| Tamsulosin | None | 12 | $57 | $5 |
2020: 57 drugs
| Rytary | Parkinson's | 1,107 | $897,223 | $810 |
| Nuplazid | Parkinson's psychosis | 56 | $266,017 | $4,750 |
| Apokyn | None | 12 | $259,319 | $21,610 |
| Northera | None | 19 | $207,408 | $10,916 |
| Gocovri | None | 79 | $135,996 | $1,721 |
| Ropinirole Er | None | 272 | $65,086 | $239 |
| Nuedexta | None | 46 | $61,908 | $1,346 |
| Carbidopa-Levodopa | None | 878 | $61,021 | $70 |
| Rasagiline Mesylate | None | 77 | $55,756 | $724 |
| Rivastigmine | None | 167 | $48,727 | $292 |
| Neupro | None | 35 | $46,651 | $1,333 |
| Myrbetriq | None | 67 | $38,744 | $578 |
| Entacapone | None | 103 | $31,608 | $307 |
| Amantadine | None | 459 | $24,238 | $53 |
| Carbidopa-Levodopa-Entacapone | None | 45 | $21,566 | $479 |
| Xadago | None | 16 | $19,673 | $1,230 |
| Pramipexole Er | None | 37 | $19,620 | $530 |
| Exelon | None | 16 | $18,299 | $1,144 |
| Carbidopa-Levodopa Er | None | 106 | $18,060 | $170 |
| Osmolex Er | None | 24 | $13,793 | $575 |
| Pramipexole Dihydrochloride | None | 225 | $11,745 | $52 |
| Midodrine | None | 49 | $11,026 | $225 |
| Myobloc | None | 18 | $9,780 | $543 |
| Galantamine Hbr | None | 41 | $5,914 | $144 |
| Mirtazapine | None | 139 | $5,482 | $39 |
| Linzess | None | 11 | $4,757 | $432 |
| Donepezil | None | 232 | $4,689 | $20 |
| Selegiline | None | 45 | $4,454 | $99 |
| Quetiapine | None | 163 | $3,341 | $20 |
| Fludrocortisone Acetate | None | 89 | $2,605 | $29 |
| Clozapine | None | 100 | $2,373 | $24 |
| Pregabalin | None | 26 | $2,034 | $78 |
| Ropinirole | None | 62 | $1,873 | $30 |
| Escitalopram | None | 148 | $1,871 | $13 |
| Clonazepam | None | 202 | $1,735 | $9 |
| Propranolol Hcl Er | None | 20 | $1,667 | $83 |
| Rivastigmine | None | 17 | $1,545 | $91 |
| Tolterodine Tartrate Er | None | 23 | $1,356 | $59 |
| Gabapentin | None | 80 | $1,097 | $14 |
| Solifenacin | None | 23 | $961 | $42 |
| Memantine | None | 27 | $943 | $35 |
| Amoxapine | None | 13 | $940 | $72 |
| Ipratropium | None | 13 | $835 | $64 |
| Zonisamide | None | 17 | $608 | $36 |
| Venlafaxine Hcl Er | None | 14 | $593 | $42 |
| Trazodone | None | 48 | $580 | $12 |
| Sertraline | None | 22 | $496 | $23 |
| Alprazolam | None | 41 | $453 | $11 |
| Primidone | None | 14 | $421 | $30 |
| Propranolol | None | 18 | $394 | $22 |
| Lorazepam | None | 59 | $385 | $7 |
| Duloxetine | None | 14 | $351 | $25 |
| Paroxetine | None | 18 | $343 | $19 |
| Temazepam | None | 27 | $338 | $13 |
| Buspirone | None | 14 | $238 | $17 |
| Citalopram Hbr | None | 11 | $202 | $18 |
| Tramadol | None | 12 | $78 | $7 |
2019: 59 drugs
| Rytary | Parkinson's | 993 | $743,815 | $749 |
| Nuplazid | Parkinson's psychosis | 64 | $289,470 | $4,523 |
| Northera | None | 22 | $249,241 | $11,329 |
| Gocovri | None | 52 | $115,885 | $2,229 |
| Neupro | None | 86 | $82,525 | $960 |
| Ropinirole Er | None | 315 | $82,315 | $261 |
| Carbidopa-Levodopa | None | 980 | $58,799 | $60 |
| Rasagiline Mesylate | None | 75 | $58,396 | $779 |
| Rivastigmine | None | 150 | $38,685 | $258 |
| Entacapone | None | 140 | $34,744 | $248 |
| Amantadine | None | 500 | $32,581 | $65 |
| Xadago | None | 27 | $28,589 | $1,059 |
| Myrbetriq | None | 37 | $25,418 | $687 |
| Nuedexta | None | 20 | $22,316 | $1,116 |
| Carbidopa-Levodopa Er | None | 195 | $21,971 | $113 |
| Carbidopa-Levodopa-Entacapone | None | 46 | $19,952 | $434 |
| Lyrica | None | 16 | $15,200 | $950 |
| Exelon | None | 20 | $14,249 | $712 |
| Midodrine | None | 103 | $13,305 | $129 |
| Pramipexole Dihydrochloride | None | 232 | $10,284 | $44 |
| Pramipexole Er | None | 21 | $9,075 | $432 |
| Galantamine Hbr | None | 49 | $7,358 | $150 |
| Namzaric | None | 11 | $4,906 | $446 |
| Mirtazapine | None | 148 | $4,897 | $33 |
| Donepezil | None | 250 | $4,826 | $19 |
| Belsomra | None | 12 | $4,373 | $364 |
| Clozapine | None | 261 | $4,370 | $17 |
| Toviaz | None | 12 | $4,249 | $354 |
| Vimpat | None | 11 | $3,256 | $296 |
| Rivastigmine | None | 21 | $3,164 | $151 |
| Fludrocortisone Acetate | None | 96 | $3,013 | $31 |
| Tolterodine Tartrate Er | None | 25 | $2,877 | $115 |
| Escitalopram | None | 163 | $2,687 | $16 |
| Selegiline | None | 31 | $2,162 | $70 |
| Quetiapine | None | 148 | $2,016 | $14 |
| Propranolol Hcl Er | None | 29 | $2,005 | $69 |
| Ropinirole | None | 58 | $1,872 | $32 |
| Memantine | None | 31 | $1,789 | $58 |
| Gabapentin | None | 79 | $1,505 | $19 |
| Clonazepam | None | 159 | $1,398 | $9 |
| Venlafaxine Hcl Er | None | 40 | $1,350 | $34 |
| Duloxetine | None | 27 | $1,339 | $50 |
| Zonisamide | None | 36 | $1,289 | $36 |
| Baclofen | None | 18 | $1,165 | $65 |
| Ipratropium | None | 18 | $1,017 | $57 |
| Trazodone | None | 60 | $792 | $13 |
| Pregabalin | None | 14 | $774 | $55 |
| Nifedipine Er | None | 11 | $664 | $60 |
| Paroxetine | None | 39 | $645 | $17 |
| Desmopressin Acetate | None | 11 | $463 | $42 |
| Lorazepam | None | 55 | $458 | $8 |
| Primidone | None | 14 | $395 | $28 |
| Alprazolam | None | 24 | $300 | $13 |
| Temazepam | None | 28 | $284 | $10 |
| Sertraline | None | 21 | $283 | $13 |
| Fluoxetine | None | 13 | $196 | $15 |
| Citalopram Hbr | None | 15 | $129 | $9 |
| Tramadol | None | 18 | $98 | $5 |
| Amlodipine Besylate | None | 11 | $50 | $5 |
2018: 54 drugs
| Rytary | Parkinson's | 546 | $372,305 | $682 |
| Northera | None | 25 | $295,353 | $11,814 |
| Nuplazid | Parkinson's psychosis | 38 | $100,507 | $2,645 |
| Neupro | None | 79 | $82,322 | $1,042 |
| Ropinirole Er | None | 314 | $70,883 | $226 |
| Carbidopa-Levodopa | None | 1,175 | $67,997 | $58 |
| Rasagiline Mesylate | None | 85 | $63,741 | $750 |
| Entacapone | None | 175 | $52,937 | $302 |
| Amantadine | None | 499 | $41,658 | $83 |
| Gocovri | None | 21 | $40,700 | $1,938 |
| Rivastigmine | None | 67 | $30,473 | $455 |
| Xadago | None | 30 | $26,583 | $886 |
| Carbidopa-Levodopa-Entacapone | None | 66 | $24,157 | $366 |
| Carbidopa-Levodopa Er | None | 237 | $18,772 | $79 |
| Namenda Xr | None | 15 | $12,604 | $840 |
| Midodrine | None | 117 | $12,519 | $107 |
| Myrbetriq | None | 23 | $11,731 | $510 |
| Pramipexole Dihydrochloride | None | 259 | $10,952 | $42 |
| Lyrica | None | 14 | $10,471 | $748 |
| Pramipexole Er | None | 25 | $5,459 | $218 |
| Mirtazapine | None | 163 | $4,951 | $30 |
| Galantamine Hbr | None | 36 | $4,789 | $133 |
| Donepezil | None | 272 | $4,203 | $15 |
| Memantine Hcl Er | None | 13 | $3,833 | $295 |
| Toviaz | None | 11 | $3,750 | $341 |
| Fludrocortisone Acetate | None | 123 | $3,627 | $29 |
| Clozapine | None | 226 | $3,095 | $14 |
| Rivastigmine | None | 26 | $2,880 | $111 |
| Quetiapine | None | 191 | $2,637 | $14 |
| Selegiline | None | 43 | $2,634 | $61 |
| Escitalopram | None | 150 | $2,590 | $17 |
| Duloxetine | None | 43 | $2,564 | $60 |
| Ropinirole | None | 85 | $2,133 | $25 |
| Propranolol Hcl Er | None | 23 | $1,923 | $84 |
| Clonazepam | None | 181 | $1,816 | $10 |
| Gabapentin | None | 54 | $1,226 | $23 |
| Venlafaxine Hcl Er | None | 35 | $1,171 | $33 |
| Memantine | None | 15 | $1,118 | $75 |
| Zonisamide | None | 50 | $894 | $18 |
| Ipratropium | None | 11 | $886 | $81 |
| Paroxetine | None | 65 | $866 | $13 |
| Trazodone | None | 75 | $780 | $10 |
| Desmopressin Acetate | None | 20 | $745 | $37 |
| Lorazepam | None | 71 | $609 | $9 |
| Polyethylene Glycol 3350 | None | 25 | $490 | $20 |
| Propranolol | None | 16 | $349 | $22 |
| Sertraline | None | 13 | $312 | $24 |
| Levetiracetam | None | 16 | $291 | $18 |
| Alprazolam | None | 29 | $253 | $9 |
| Temazepam | None | 21 | $229 | $11 |
| Zolpidem | None | 16 | $101 | $6 |
| Citalopram Hbr | None | 12 | $70 | $6 |
| Diazepam | None | 14 | $68 | $5 |
| Clonidine | None | 12 | $41 | $3 |
2017: 51 drugs
| Rytary | Parkinson's | 255 | $171,267 | $672 |
| Entacapone | None | 235 | $94,018 | $400 |
| Neupro | None | 107 | $91,406 | $854 |
| Carbidopa-Levodopa | None | 1,319 | $73,449 | $56 |
| Rasagiline Mesylate | None | 79 | $60,020 | $760 |
| Nuplazid | Parkinson's psychosis | 22 | $51,365 | $2,335 |
| Azilect | None | 50 | $51,159 | $1,023 |
| Ropinirole Er | None | 237 | $48,673 | $205 |
| Amantadine | None | 532 | $43,241 | $81 |
| Rivastigmine | None | 63 | $26,995 | $428 |
| Namenda Xr | None | 38 | $23,158 | $609 |
| Carbidopa-Levodopa-Entacapone | None | 56 | $21,993 | $393 |
| Carbidopa-Levodopa Er | None | 319 | $20,561 | $64 |
| Pramipexole Dihydrochloride | None | 314 | $15,305 | $49 |
| Exelon | None | 21 | $13,889 | $661 |
| Pramipexole Er | None | 32 | $13,522 | $423 |
| Myrbetriq | None | 27 | $13,100 | $485 |
| Lyrica | None | 21 | $12,345 | $588 |
| Midodrine | None | 102 | $10,508 | $103 |
| Vesicare | None | 11 | $6,925 | $630 |
| Mirtazapine | None | 171 | $4,217 | $25 |
| Galantamine Hbr | None | 30 | $3,541 | $118 |
| Ropinirole | None | 123 | $3,228 | $26 |
| Donepezil | None | 261 | $3,223 | $12 |
| Fludrocortisone Acetate | None | 118 | $3,206 | $27 |
| Selegiline | None | 30 | $2,769 | $92 |
| Clozapine | None | 150 | $2,374 | $16 |
| Propranolol Hcl Er | None | 16 | $2,086 | $130 |
| Quetiapine | None | 198 | $2,011 | $10 |
| Escitalopram | None | 150 | $1,991 | $13 |
| Duloxetine | None | 28 | $1,695 | $61 |
| Gabapentin | None | 74 | $1,530 | $21 |
| Tolterodine | None | 12 | $1,448 | $121 |
| Clonazepam | None | 182 | $1,442 | $8 |
| Rivastigmine | None | 22 | $1,269 | $58 |
| Zonisamide | None | 55 | $1,242 | $23 |
| Paroxetine | None | 80 | $1,206 | $15 |
| Venlafaxine Hcl Er | None | 49 | $1,142 | $23 |
| Primidone | None | 14 | $908 | $65 |
| Trazodone | None | 100 | $830 | $8 |
| Memantine | None | 14 | $721 | $52 |
| Polyethylene Glycol 3350 | None | 30 | $711 | $24 |
| Lorazepam | None | 69 | $578 | $8 |
| Sertraline | None | 26 | $471 | $18 |
| Levetiracetam | None | 23 | $344 | $15 |
| Oxybutynin Chloride Er | None | 13 | $334 | $26 |
| Alprazolam | None | 18 | $204 | $11 |
| Zolpidem | None | 11 | $187 | $17 |
| Trihexyphenidyl | None | 20 | $147 | $7 |
| Citalopram Hbr | None | 13 | $93 | $7 |
| Diazepam | None | 21 | $85 | $4 |
2016: 54 drugs
| Northera | None | 46 | $295,122 | $6,416 |
| Rytary | Parkinson's | 287 | $194,787 | $679 |
| Azilect | None | 159 | $136,641 | $859 |
| Entacapone | None | 299 | $113,464 | $379 |
| Neupro | None | 166 | $111,298 | $670 |
| Carbidopa-Levodopa | None | 1,349 | $50,738 | $38 |
| Amantadine | None | 552 | $39,125 | $71 |
| Rivastigmine | None | 73 | $32,250 | $442 |
| Namenda Xr | None | 50 | $26,183 | $524 |
| Pramipexole Dihydrochloride | None | 389 | $23,193 | $60 |
| Carbidopa-Levodopa-Entacapone | None | 48 | $16,358 | $341 |
| Carbidopa-Levodopa Er | None | 360 | $16,316 | $45 |
| Ropinirole Er | None | 62 | $15,640 | $252 |
| Myrbetriq | None | 24 | $13,458 | $561 |
| Botox | None | 13 | $12,576 | $967 |
| Nuedexta | None | 12 | $8,426 | $702 |
| Lyrica | None | 15 | $8,185 | $546 |
| Pramipexole Er | None | 16 | $6,383 | $399 |
| Exelon | None | 12 | $6,360 | $530 |
| Galantamine Hbr | None | 59 | $5,595 | $95 |
| Midodrine | None | 56 | $4,602 | $82 |
| Donepezil | None | 299 | $4,465 | $15 |
| Mirtazapine | None | 220 | $4,240 | $19 |
| Ropinirole | None | 134 | $3,664 | $27 |
| Selegiline | None | 54 | $3,659 | $68 |
| Clozapine | None | 128 | $3,502 | $27 |
| Quetiapine | None | 207 | $2,767 | $13 |
| Propranolol Hcl Er | None | 34 | $2,545 | $75 |
| Fludrocortisone Acetate | None | 105 | $2,513 | $24 |
| Clonazepam | None | 154 | $1,473 | $10 |
| Desmopressin Acetate | None | 22 | $1,330 | $60 |
| Lorazepam | None | 95 | $1,211 | $13 |
| Escitalopram | None | 94 | $1,192 | $13 |
| Rivastigmine | None | 15 | $1,035 | $69 |
| Gabapentin | None | 69 | $994 | $14 |
| Memantine | None | 18 | $963 | $53 |
| Duloxetine | None | 17 | $913 | $54 |
| Zonisamide | None | 46 | $670 | $15 |
| Pyridostigmine | None | 15 | $607 | $40 |
| Fluoxetine | None | 28 | $589 | $21 |
| Paroxetine | None | 50 | $589 | $12 |
| Venlafaxine Hcl Er | None | 41 | $578 | $14 |
| Levetiracetam | None | 28 | $507 | $18 |
| Trazodone | None | 52 | $460 | $9 |
| Sertraline | None | 18 | $413 | $23 |
| Venlafaxine | None | 11 | $372 | $34 |
| Ipratropium | None | 11 | $319 | $29 |
| Alprazolam | None | 13 | $302 | $23 |
| Polyethylene Glycol 3350 | None | 14 | $269 | $19 |
| Oxybutynin Chloride Er | None | 11 | $264 | $24 |
| Citalopram Hbr | None | 23 | $225 | $10 |
| Trihexyphenidyl | None | 26 | $153 | $6 |
| Tramadol | None | 16 | $141 | $9 |
| Omeprazole | None | 11 | $94 | $9 |
2015: 50 drugs
| Azilect | None | 224 | $167,370 | $747 |
| Rytary | Parkinson's | 235 | $148,220 | $631 |
| Northera | None | 21 | $108,509 | $5,167 |
| Neupro | None | 116 | $86,901 | $749 |
| Carbidopa-Levodopa | None | 1,291 | $58,853 | $46 |
| Entacapone | None | 105 | $46,843 | $446 |
| Amantadine | None | 592 | $45,200 | $76 |
| Exelon | None | 41 | $25,749 | $628 |
| Pramipexole Dihydrochloride | None | 397 | $21,736 | $55 |
| Carbidopa-Levodopa Er | None | 414 | $20,096 | $49 |
| Namenda Xr | None | 38 | $17,271 | $454 |
| Ropinirole Er | None | 54 | $16,091 | $298 |
| Carbidopa-Levodopa-Entacapone | None | 47 | $15,553 | $331 |
| Myrbetriq | None | 39 | $14,275 | $366 |
| Desmopressin Acetate | None | 30 | $4,224 | $141 |
| Galantamine Hbr | None | 32 | $4,142 | $129 |
| Selegiline | None | 60 | $3,703 | $62 |
| Clozapine | None | 116 | $3,639 | $31 |
| Donepezil | None | 265 | $3,567 | $13 |
| Mirtazapine | None | 233 | $3,528 | $15 |
| Midodrine | None | 31 | $2,698 | $87 |
| Fludrocortisone Acetate | None | 92 | $2,604 | $28 |
| Ropinirole | None | 108 | $2,432 | $23 |
| Quetiapine | None | 184 | $1,799 | $10 |
| Propranolol Hcl Er | None | 25 | $1,459 | $58 |
| Clonazepam | None | 135 | $805 | $6 |
| Gabapentin | None | 77 | $773 | $10 |
| Doxepin | None | 12 | $610 | $51 |
| Paroxetine | None | 53 | $599 | $11 |
| Bupropion Xl | None | 19 | $537 | $28 |
| Zonisamide | None | 37 | $527 | $14 |
| Fluoxetine | None | 30 | $515 | $17 |
| Ipratropium | None | 12 | $503 | $42 |
| Venlafaxine Hcl Er | None | 36 | $484 | $13 |
| Sertraline | None | 33 | $474 | $14 |
| Escitalopram | None | 34 | $423 | $12 |
| Venlafaxine | None | 12 | $399 | $33 |
| Polyethylene Glycol 3350 | None | 24 | $383 | $16 |
| Trihexyphenidyl | None | 25 | $351 | $14 |
| Lorazepam | None | 53 | $346 | $7 |
| Levetiracetam | None | 35 | $320 | $9 |
| Oxybutynin Chloride | None | 22 | $267 | $12 |
| Trazodone | None | 50 | $249 | $5 |
| Nifedipine Er | None | 12 | $217 | $18 |
| Propranolol | None | 11 | $186 | $17 |
| Alprazolam | None | 12 | $170 | $14 |
| Tramadol | None | 16 | $98 | $6 |
| Baclofen | None | 11 | $97 | $9 |
| Losartan | None | 13 | $85 | $7 |
| Atorvastatin | None | 11 | $80 | $7 |
2014: 49 drugs
| Azilect | 280 | $187,246 | $669 |
| Neupro | 100 | $70,487 | $705 |
| Carbidopa-Levodopa | 1,084 | $61,224 | $56 |
| Entacapone | 116 | $58,079 | $501 |
| Amantadine | 526 | $43,936 | $84 |
| Carbidopa-Levodopa-Entacapone | 54 | $26,508 | $491 |
| Carbidopa-Levodopa Er | 480 | $21,782 | $45 |
| Exelon | 35 | $20,272 | $579 |
| Pramipexole Dihydrochloride | 309 | $17,896 | $58 |
| Namenda | 47 | $15,357 | $327 |
| Myrbetriq | 48 | $14,540 | $303 |
| Ropinirole | 157 | $14,302 | $91 |
| Namenda Xr | 24 | $10,570 | $440 |
| Nuvigil | 18 | $9,493 | $527 |
| Carbidopa | 11 | $7,544 | $686 |
| Comtan | 11 | $7,410 | $674 |
| Selegiline | 56 | $5,226 | $93 |
| Quetiapine | 159 | $4,719 | $30 |
| Vesicare | 11 | $4,235 | $385 |
| Donepezil | 221 | $3,210 | $15 |
| Fludrocortisone Acetate | 118 | $2,891 | $25 |
| Mirtazapine | 162 | $2,679 | $17 |
| Midodrine | 28 | $2,638 | $94 |
| Galantamine Hbr | 20 | $2,580 | $129 |
| Desmopressin Acetate | 29 | $2,495 | $86 |
| Clozapine | 166 | $2,404 | $14 |
| Venlafaxine Hcl Er | 58 | $1,281 | $22 |
| Paroxetine | 66 | $891 | $14 |
| Gabapentin | 71 | $815 | $11 |
| Escitalopram | 22 | $699 | $32 |
| Sertraline | 45 | $668 | $15 |
| Clonazepam | 86 | $619 | $7 |
| Propranolol Hcl Er | 12 | $611 | $51 |
| Primidone | 13 | $544 | $42 |
| Venlafaxine | 15 | $479 | $32 |
| Lorazepam | 55 | $416 | $8 |
| Levetiracetam | 15 | $389 | $26 |
| Levetiracetam Er | 15 | $327 | $22 |
| Alprazolam | 22 | $261 | $12 |
| Citalopram Hbr | 18 | $255 | $14 |
| Bupropion Xl | 12 | $252 | $21 |
| Trihexyphenidyl | 17 | $219 | $13 |
| Oxybutynin Chloride | 14 | $215 | $15 |
| Fluoxetine | 25 | $199 | $8 |
| Trazodone | 35 | $190 | $5 |
| Temazepam | 20 | $141 | $7 |
| Nifedipine Er | 11 | $132 | $12 |
| Lactulose | 16 | $129 | $8 |
| Baclofen | 17 | $117 | $7 |
2013: 48 drugs
| Azilect | 236 | $142,256 | $603 |
| Neupro | 152 | $69,951 | $460 |
| Carbidopa-Levodopa | 1,014 | $64,573 | $64 |
| Entacapone | 88 | $50,818 | $577 |
| Amantadine | 423 | $39,777 | $94 |
| Namenda | 92 | $30,998 | $337 |
| Carbidopa-Levodopa-Entacapone | 42 | $27,523 | $655 |
| Exelon | 64 | $25,775 | $403 |
| Comtan | 41 | $24,791 | $605 |
| Carbidopa-Levodopa Er | 416 | $20,130 | $48 |
| Pramipexole Dihydrochloride | 278 | $18,531 | $67 |
| Ropinirole | 119 | $17,414 | $146 |
| Mirapex Er | 16 | $9,924 | $620 |
| Quetiapine | 181 | $7,144 | $39 |
| Modafinil | 11 | $6,573 | $598 |
| Myrbetriq | 25 | $5,543 | $222 |
| Lodosyn | 15 | $4,362 | $291 |
| Donepezil | 207 | $4,229 | $20 |
| Midodrine | 34 | $4,178 | $123 |
| Galantamine Hbr | 27 | $3,975 | $147 |
| Selegiline | 31 | $3,682 | $119 |
| Mirtazapine | 250 | $3,325 | $13 |
| Fludrocortisone Acetate | 118 | $3,239 | $27 |
| Venlafaxine Hcl Er | 65 | $1,625 | $25 |
| Gabapentin | 74 | $1,120 | $15 |
| Paroxetine | 56 | $1,096 | $20 |
| Oxybutynin Chloride Er | 17 | $1,058 | $62 |
| Clozapine | 103 | $980 | $10 |
| Sertraline | 43 | $739 | $17 |
| Escitalopram | 16 | $736 | $46 |
| Primidone | 12 | $637 | $53 |
| Polyethylene Glycol 3350 | 24 | $609 | $25 |
| Bupropion Xl | 21 | $592 | $28 |
| Lorazepam | 66 | $562 | $9 |
| Topiramate | 16 | $484 | $30 |
| Levetiracetam | 15 | $456 | $30 |
| Clonazepam | 63 | $415 | $7 |
| Propranolol | 16 | $251 | $16 |
| Alprazolam | 23 | $248 | $11 |
| Imipramine | 12 | $182 | $15 |
| Fluoxetine | 25 | $173 | $7 |
| Zolpidem | 17 | $166 | $10 |
| Pantoprazole | 12 | $131 | $11 |
| Citalopram Hbr | 14 | $125 | $9 |
| Temazepam | 18 | $124 | $7 |
| Trazodone | 18 | $111 | $6 |
| Clonidine | 13 | $91 | $7 |
| Trihexyphenidyl | 13 | $70 | $5 |
Money from drug and device companies
$4,301 in 2025
| 2025 | 15 | 135 | $292 | $4,301 |
| 2024 | 16 | 162 | $850 | $5,526 |
| 2023 | 17 | 173 | $5,000 | $11,519 |
| 2022 | 21 | 262 | $5,850 | $14,237 |
| 2021 | 26 | 229 | $9,295 | $14,944 |
| 2020 | 23 | 191 | $1,395 | $6,355 |
| 2019 | 22 | 235 | $18,452 | $27,085 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| MDD US Operations | Gocovri | $880 | 25 payments
|
| Abbvie | Vyalev | $735 | 32 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $641 | 18 payments
|
| Boston Scientific | General - Dbs | $506 | 6 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $489 | 17 payments
|
| Neurocrine BioSciences | Ingrezza | $298 | 12 payments
|
See all 135 published payments
| Boston Scientific | Meals · 2025-12-05 | General - Dbs | $87 |
| Abbvie | Meals · 2025-12-02 | Vyalev | $34 |
| Teva Pharmaceuticals USA | Meals · 2025-11-24 | Austedo Xr | $31 |
| ACADIA Pharmaceuticals | Meals · 2025-11-22 | Nuplazid | $24 |
| Abbvie | Meals · 2025-11-19 | Vyalev | $25 |
| Amneal Pharmaceuticals | Meals · 2025-11-18 | Crexont | $19 |
| ACADIA Pharmaceuticals | Meals · 2025-11-13 | Nuplazid | $33 |
| Abbvie | Meals · 2025-11-12 | Botox | $31 |
| MDD US Operations | Meals · 2025-11-07 | Gocovri | $43 |
| Amneal Pharmaceuticals | Meals · 2025-11-03 | Crexont | $16 |
| ACADIA Pharmaceuticals | Meals · 2025-10-31 | Nuplazid | $23 |
| Teva Pharmaceuticals USA | Meals · 2025-10-29 | Austedo Xr | $14 |
| Neurocrine BioSciences | Meals · 2025-10-23 | Ingrezza | $38 |
| Teva Pharmaceuticals USA | Meals · 2025-10-23 | Austedo Xr | $37 |
| Amneal Pharmaceuticals | Meals · 2025-10-20 | Crexont | $23 |
| Boston Scientific | Meals · 2025-10-17 | General - Dbs | $30 |
| Abbvie | Meals · 2025-10-16 | Vyalev | $33 |
| Abbvie | Meals · 2025-10-14 | Botox | $32 |
| Abbvie | Meals · 2025-10-09 | Vyalev | $8 |
| Amneal Pharmaceuticals | Meals · 2025-10-08 | Crexont | $18 |
| InSightec | Meals · 2025-10-07 | Exablate | $146 |
| MDD US Operations | Meals · 2025-10-07 | None | $46 |
| Abbvie | Meals · 2025-10-04 | Vyalev | $35 |
| MDD US Operations | Meals · 2025-10-02 | None | $26 |
| ACADIA Pharmaceuticals | Meals · 2025-10-02 | Nuplazid | $33 |
| Abbvie | Meals · 2025-09-29 | Vyalev | $17 |
| Medtronic | Meals · 2025-09-29 | Percept PC Brainsense | $47 |
| Boston Scientific | Meals · 2025-09-25 | General - Dbs | $146 |
| Teva Pharmaceuticals USA | Meals · 2025-09-24 | Austedo Xr | $32 |
| MDD US Operations | Meals · 2025-09-18 | None | $42 |
| Abbvie | Meals · 2025-09-17 | Vyalev | $29 |
| Neurocrine BioSciences | Meals · 2025-09-16 | Ingrezza | $33 |
| Neurocrine BioSciences | Meals · 2025-09-16 | Ingrezza | $7 |
| Neurocrine BioSciences | Meals · 2025-09-16 | Ingrezza | $7 |
| MDD US Operations | Meals · 2025-09-12 | None | $49 |
| ACADIA Pharmaceuticals | Meals · 2025-09-11 | Nuplazid | $32 |
| Abbvie | Meals · 2025-09-10 | Qulipta | $30 |
| Teva Pharmaceuticals USA | Meals · 2025-09-10 | Austedo Xr | $10 |
| Merz Pharmaceuticals | Meals · 2025-09-08 | Inbrija | $46 |
| Abbvie | Meals · 2025-09-05 | Botox | $22 |
| Abbvie | Meals · 2025-09-04 | Vyalev | $28 |
| MDD US Operations | Meals · 2025-09-04 | None | $46 |
| MDD US Operations | Meals · 2025-08-20 | None | $15 |
| Teva Pharmaceuticals USA | Meals · 2025-08-19 | Austedo Xr | $35 |
| Medtronic | Meals · 2025-08-18 | Percept PC Brainsense | $40 |
| MDD US Operations | Meals · 2025-08-15 | None | $4 |
| Tanabe Pharma America | Meals · 2025-08-13 | Radicava | $24 |
| ACADIA Pharmaceuticals | Meals · 2025-08-12 | Nuplazid | $35 |
| Abbvie | Meals · 2025-08-05 | Vyalev | $31 |
| MDD US Operations | Meals · 2025-08-05 | None | $39 |
| Teva Pharmaceuticals USA | Meals · 2025-07-30 | Austedo Xr | $29 |
| Teva Pharmaceuticals USA | Meals · 2025-07-29 | Austedo Xr | $33 |
| Neurocrine BioSciences | Meals · 2025-07-26 | Ingrezza | $11 |
| Abbvie | Meals · 2025-07-23 | Botox | $24 |
| Merz Pharmaceuticals | Meals · 2025-07-23 | Inbrija | $34 |
| ACADIA Pharmaceuticals | Meals · 2025-07-22 | Nuplazid | $43 |
| ACADIA Pharmaceuticals | Meals · 2025-07-18 | Nuplazid | $29 |
| Ipsen Biopharmaceuticals | Meals · 2025-07-15 | Dysport | $23 |
| Neurocrine BioSciences | Meals · 2025-07-10 | Ingrezza | $40 |
| MDD US Operations | Paid to speak or teach · 2025-07-08 | None | $22 |
| Teva Pharmaceuticals USA | Education · 2025-07-08 | None | $111 |
| Teva Pharmaceuticals USA | Meals · 2025-07-02 | Austedo Xr | $31 |
| ACADIA Pharmaceuticals | Meals · 2025-07-01 | Nuplazid | $27 |
| MDD US Operations | Meals · 2025-06-30 | None | $6 |
| MDD US Operations | Meals · 2025-06-24 | None | $9 |
| MDD US Operations | Meals · 2025-06-18 | None | $26 |
| Abbvie | Meals · 2025-06-13 | Botox | $29 |
| Neurocrine BioSciences | Meals · 2025-06-12 | Ingrezza | $37 |
| ACADIA Pharmaceuticals | Meals · 2025-06-10 | Nuplazid | $24 |
| Boston Scientific | Meals · 2025-06-04 | General - Dbs | $31 |
| Teva Pharmaceuticals USA | Meals · 2025-06-04 | Austedo Xr | $4 |
| Teva Pharmaceuticals USA | Meals · 2025-06-04 | Austedo Xr | $38 |
| MDD US Operations | Paid to speak or teach · 2025-06-03 | None | $20 |
| ACADIA Pharmaceuticals | Meals · 2025-06-03 | Nuplazid | $7 |
| Amneal Pharmaceuticals | Meals · 2025-05-29 | Rytary | $28 |
| Teva Pharmaceuticals USA | Meals · 2025-05-29 | Austedo Xr | $12 |
| Abbvie | Meals · 2025-05-22 | Botox | $25 |
| Teva Pharmaceuticals USA | Meals · 2025-05-14 | Austedo Xr | $38 |
| ACADIA Pharmaceuticals | Meals · 2025-05-09 | Nuplazid | $24 |
| MDD US Operations | Meals · 2025-05-08 | None | $16 |
| MDD US Operations | Meals · 2025-05-07 | None | $36 |
| Amneal Pharmaceuticals | Meals · 2025-05-06 | Rytary | $24 |
| Neurocrine BioSciences | Meals · 2025-05-06 | Ingrezza | $27 |
| Neurocrine BioSciences | Meals · 2025-05-06 | Ingrezza | $17 |
| MDD US Operations | Meals · 2025-05-02 | None | $12 |
| Amneal Pharmaceuticals | Meals · 2025-05-01 | Rytary | $4 |
| Amneal Pharmaceuticals | Meals · 2025-05-01 | Rytary | $4 |
| Merz Pharmaceuticals | Meals · 2025-05-01 | Xeomin | $44 |
| Abbvie | Meals · 2025-04-29 | Botox | $25 |
| Boston Scientific | Meals · 2025-04-25 | General - Dbs | $92 |
| Amneal Pharmaceuticals | Meals · 2025-04-18 | Rytary | $3 |
| Teva Pharmaceuticals USA | Meals · 2025-04-17 | Austedo Xr | $31 |
| Biogen | Meals · 2025-04-16 | Skyclarys | $25 |
| MDD US Operations | Meals · 2025-04-16 | None | $20 |
| MDD US Operations | Meals · 2025-04-16 | None | $19 |
| ACADIA Pharmaceuticals | Meals · 2025-04-16 | Nuplazid | $32 |
| Abbvie | Meals · 2025-04-15 | Vyalev | $33 |
| Amneal Pharmaceuticals | Meals · 2025-04-09 | Rytary | $21 |
| MDD US Operations | Honoraria · 2025-04-08 | Gocovri | $250 |
| Teva Pharmaceuticals USA | Education · 2025-04-04 | None | $81 |
| Boston Scientific | Meals · 2025-04-02 | General - Dbs | $121 |
| Amneal Pharmaceuticals | Meals · 2025-03-26 | Rytary | $29 |
| MDD US Operations | Meals · 2025-03-19 | None | $30 |
| ACADIA Pharmaceuticals | Meals · 2025-03-19 | Nuplazid | $30 |
| Abbvie | Meals · 2025-03-11 | Ubrelvy | $16 |
| Abbvie | Meals · 2025-03-07 | Qulipta | $14 |
| MDD US Operations | Meals · 2025-03-06 | None | $33 |
| Teva Pharmaceuticals USA | Meals · 2025-03-06 | Austedo Xr | $38 |
| Abbvie | Meals · 2025-02-28 | Botox | $30 |
| ACADIA Pharmaceuticals | Meals · 2025-02-25 | Nuplazid | $32 |
| Lundbeck | Meals · 2025-02-25 | Rexulti | $25 |
| MDD US Operations | Meals · 2025-02-21 | None | $37 |
| Abbvie | Meals · 2025-02-20 | Qulipta | $19 |
| ACADIA Pharmaceuticals | Meals · 2025-02-18 | Nuplazid | $33 |
| Abbvie | Meals · 2025-02-14 | Vyalev | $8 |
| MDD US Operations | Meals · 2025-02-14 | None | $15 |
| Amneal Pharmaceuticals | Meals · 2025-02-10 | Rytary | $28 |
| Neurocrine BioSciences | Meals · 2025-02-07 | Ingrezza | $34 |
| Abbvie | Meals · 2025-02-05 | Ubrelvy | $18 |
| MDD US Operations | Meals · 2025-02-05 | None | $19 |
| Abbvie | Meals · 2025-02-04 | Qulipta | $13 |
| Lundbeck | Meals · 2025-02-04 | Rexulti | $24 |
| Abbvie | Meals · 2025-01-31 | Botox | $35 |
| Abbvie | Meals · 2025-01-30 | Vyalev | $29 |
| Amneal Pharmaceuticals | Meals · 2025-01-28 | Rytary | $27 |
| Abbvie | Meals · 2025-01-27 | Ubrelvy | $18 |
| ACADIA Pharmaceuticals | Meals · 2025-01-24 | Nuplazid | $26 |
| Neurocrine BioSciences | Meals · 2025-01-23 | Ingrezza | $15 |
| Revance Therapeutics | Meals · 2025-01-22 | Daxi | $28 |
| Abbvie | Meals · 2025-01-17 | Vyalev | $14 |
| Abbvie | Meals · 2025-01-17 | Vyalev | $13 |
| Teva Pharmaceuticals USA | Meals · 2025-01-16 | Austedo Xr | $32 |
| Abbvie | Meals · 2025-01-10 | Qulipta | $10 |
| Neurocrine BioSciences | Meals · 2025-01-07 | Ingrezza | $32 |
| Abbvie | Meals · 2025-01-05 | Vyalev | $8 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $5,526
| Boston Scientific | Vercise | $1,133 | 8 payments
|
| Abbvie | Qulipta | $1,049 | 42 payments
|
| MDD US Operations | Gocovri | $1,032 | 31 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $543 | 18 payments
|
| Kyowa Kirin | Nourianz | $345 | 10 payments
|
| Neurocrine Biosciences | Ingrezza | $317 | 11 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $282 | 10 payments
|
| Acorda Therapeutics | Inbrija | $181 | 10 payments
|
| Amneal Pharmaceuticals | Rytary | $163 | 8 payments
|
| InSightec | Exablate | $125 | 1 payment
|
| Revance Therapeutics | Daxxify | $113 | 5 payments
|
| Merz Pharmaceuticals | Xeomin | $100 | 3 payments
|
| Otsuka America Pharmaceutical | Nuedexta | $51 | 2 payments
|
| Medtronic | Percept PC Brainsense | $40 | 1 payment
|
| Lilly USA | Emgality | $29 | 1 payment
|
| Abbott Laboratories | Infinity | $25 | 1 payment
|
2023: $11,519
| Boston Scientific | Vercise | $7,281 | 12 payments
|
| Abbvie | Duopa | $867 | 35 payments
|
| MDD US Operations | None | $689 | 27 payments
|
| Neurocrine Biosciences | Ingrezza | $616 | 14 payments
|
| Teva Pharmaceuticals USA | Austedo Xr | $553 | 21 payments
|
| Acorda Therapeutics | Inbrija | $318 | 21 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $225 | 8 payments
|
| InSightec | Exablate | $197 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $140 | 7 payments
|
| Otsuka America Pharmaceutical | Nuedexta | $136 | 7 payments
|
| Medtronic | Percept PC Brainsense | $132 | 4 payments
|
| Kyowa Kirin | Nourianz | $111 | 5 payments
|
| Merz Pharmaceuticals | Xeomin | $104 | 3 payments
|
| Impel Pharmaceuticals | Trudhesa | $77 | 4 payments
|
| GE HealthCare | None | $35 | 1 payment
|
| Pfizer | Nurtec Odt | $19 | 1 payment
|
| Cala Health | Cala Trio | $17 | 1 payment
|
2022: $14,237
| Neurocrine BioSciences | Ingrezza | $7,374 | 20 payments
|
| Medtronic | Percept PC Brainsense | $1,484 | 12 payments
|
| Boston Scientific | Vercise | $1,095 | 21 payments
|
| Abbvie | Duopa | $902 | 44 payments
|
| MDD US Operations | Xadago | $683 | 36 payments
|
| Teva Pharmaceuticals USA | Austedo | $454 | 12 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $356 | 26 payments
|
| Kyowa Kirin | Nourianz | $290 | 18 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $274 | 14 payments
|
| Avanir Pharmaceuticals | Nuedexta | $242 | 15 payments
|
| Abbott Laboratories | Infinity | $241 | 4 payments
|
| Acorda Therapeutics | Inbrija | $228 | 14 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $200 | 10 payments
|
| Avion Pharmaceuticals | Dhivy | $147 | 7 payments
|
| Merz Pharmaceuticals | Xeomin | $97 | 3 payments
|
| Ipsen Biopharmaceuticals | Dysport | $34 | 1 payment
|
| Ucb | Neupro | $32 | 1 payment
|
| Lilly USA | Emgality | $31 | 1 payment
|
| GE HealthCare | None | $28 | 1 payment
|
| Allergan | Botox | $24 | 1 payment
|
| Amneal Pharmaceuticals | Rytary | $19 | 1 payment
|
2021: $14,944
| Neurocrine Biosciences | Ongentys | $9,538 | 25 payments
|
| Boston Scientific | General Dbs | $1,033 | 20 payments
|
| Adamas Pharmaceuticals | Gocovri | $542 | 21 payments
|
| AbbVie | Duopa | $492 | 20 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $492 | 27 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $381 | 13 payments
|
| Abbott Laboratories | Infinity Dbs Pulse Generators | $368 | 6 payments
|
| Ucb | Neupro | $324 | 13 payments
|
| Kyowa Kirin | Nourianz | $237 | 15 payments
|
| Teva Pharmaceuticals USA | Ajovy | $233 | 11 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $198 | 8 payments
|
| Acorda Therapeutics | Inbrija | $182 | 8 payments
|
| Avanir Pharmaceuticals | Nuedexta | $168 | 6 payments
|
| MDD US Operations | Apokyn | $131 | 8 payments
|
| Lilly USA | Emgality | $86 | 4 payments
|
| Allergan | Botox | $86 | 5 payments
|
| Merz Pharmaceuticals | Xeomin | $70 | 3 payments
|
| Medtronic | Percept | $69 | 2 payments
|
| Amneal Pharmaceuticals | Rytary | $64 | 3 payments
|
| Arbor Pharmaceuticals | Horizant | $61 | 3 payments
|
| Ge Healthcare | None | $58 | 2 payments
|
| Lundbeck | Northera | $41 | 2 payments
|
| Amgen | Aimovig | $24 | 1 payment
|
| Novartis Pharmaceuticals | Aimovig | $24 | 1 payment
|
| Ipsen Biopharmaceuticals | Dysport | $23 | 1 payment
|
| Avion Pharmaceuticals | None | $19 | 1 payment
|
2020: $6,355
| Neurocrine Biosciences | Ingrezza | $1,454 | 8 payments
|
| Acorda Therapeutics | Inbrija | $1,375 | 14 payments
|
| Boston Scientific | General - Dbs | $343 | 8 payments
|
| US WorldMeds | Xadago | $339 | 15 payments
|
| Kyowa Kirin | Nourianz | $311 | 16 payments
|
| Ucb | Neupro | $295 | 13 payments
|
| Abbott Laboratories | Infinity Dbs Pulse Generators | $256 | 6 payments
|
| Adamas Pharmaceuticals | Gocovri | $255 | 14 payments
|
| Avanir Pharmaceuticals | Nuedexta | $244 | 11 payments
|
| Amneal Pharmaceuticals | Rytary | $218 | 16 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $217 | 16 payments
|
| AbbVie | Duopa | $188 | 10 payments
|
| Allergan | Botox | $179 | 12 payments
|
| Sunovion Pharmaceuticals | Kynmobi | $160 | 8 payments
|
| Merz North America | Xeomin | $130 | 6 payments
|
| Lundbeck | Northera | $91 | 4 payments
|
| Teva Pharmaceuticals USA | Austedo | $67 | 3 payments
|
| Ge Healthcare | None | $58 | 3 payments
|
| Medtronic USA | Activa | $47 | 2 payments
|
| Ipsen Biopharmaceuticals | Dysport | $46 | 2 payments
|
| Novartis Pharmaceuticals | Aimovig | $35 | 2 payments
|
| Amgen | Aimovig | $26 | 1 payment
|
| Lilly USA | Emgality | $20 | 1 payment
|
2019: $27,085
| US WorldMeds | Myobloc | $10,882 | 46 payments
|
| Acorda Therapeutics | Inbrija | $10,185 | 12 payments
|
| Adamas Pharmaceuticals | Gocovri | $1,623 | 16 payments
|
| Boston Scientific | General Dbs | $1,000 | 9 payments
|
| Ucb | Neupro | $538 | 22 payments
|
| ACADIA Pharmaceuticals | Nuplazid | $505 | 34 payments
|
| Medtronic USA | Activa | $487 | 5 payments
|
| Amneal Pharmaceuticals | Rytary | $412 | 17 payments
|
| Avanir Pharmaceuticals | Nuedexta | $253 | 11 payments
|
| AbbVie | Duopa | $199 | 11 payments
|
| Amgen | Aimovig | $156 | 6 payments
|
| Allergan | Botox | $142 | 12 payments
|
| Lundbeck | Northera | $135 | 6 payments
|
| Merz North America | Xeomin | $116 | 7 payments
|
| Abbott Laboratories | Infinity Dbs Pulse Generators | $103 | 4 payments
|
| Ipsen Biopharmaceuticals | Dysport | $99 | 4 payments
|
| Vertical Pharmaceuticals | Osmolex Er | $92 | 5 payments
|
| Kyowa Kirin | Nourianz | $47 | 3 payments
|
| Novartis Pharmaceuticals | Aimovig | $44 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $28 | 1 payment
|
| Lilly USA | Emgality | $22 | 1 payment
|
| Sunovion Pharmaceuticals | None | $16 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Neurocrine Biosciences, Inc. · Opicapone Treatment Initiation Open-Label Study · 2023 | This clinician | $6,997 |
Checkups this office reported
5 measures · 2023
Medicare asked this office to report how often certain checkups happened in 2023. This is not a grade for the doctor. A specialist’s patients may not need every screening.
- Medicare’s overall office score
- 89.2 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
| Advance care plan on fileOlder patients with an advance care plan or a documented conversation about one | 81%That's most of the people this applied to. | 659 |
| Assessment of Cognitive Impairment or Dysfunction for Patients with Parkinson's DiseaseAs Medicare defines this measure | 62% | 187 |
| Falls: Plan of CareAs Medicare defines this measure | 100% | 150 |
| Medications listed in the chartVisits where the current medication list was documented | 93%That's most of the people this applied to. | 3,305 |
| Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and OlderAs Medicare defines this measure | 96% | 251 |
What the office says it does
Boxes the office ticked on its Medicare worksheet for 2023. Nobody checks these.
- Drug Cost Transparency
- Offers telehealth visits
- Records advance care plans
Professional record
- NPI
- 1740212547
- Licence
- CA A82711California A82711: Current · expires 2028-09-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 4701 Cherrywood Dr, San Jose, CA, 95129
- NPI first listed
- 2006-07-06
- NPI last updated
- 2013-07-29
This is when the NPI record was last certified, not a medical board exam.